Literature DB >> 28573331

FDG-PET/CT for systemic staging of patients with newly diagnosed breast cancer.

David Groheux1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28573331     DOI： 10.1007/s00259-017-3731-3

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  20 in total

1.  Early monitoring of response to neoadjuvant chemotherapy in breast cancer with 18F-FDG PET/CT: defining a clinical aim.

Authors:  David Groheux; Sylvie Giacchetti; Marc Espié; Domenico Rubello; Jean-luc Moretti; Elif Hindié
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-03       Impact factor: 9.236

2.  Comparison of 18F-FDG PET/CT for Systemic Staging of Newly Diagnosed Invasive Lobular Carcinoma Versus Invasive Ductal Carcinoma.

Authors:  Molly P Hogan; Debra A Goldman; Brittany Dashevsky; Christopher C Riedl; Mithat Gönen; Joseph R Osborne; Maxine Jochelson; Clifford Hudis; Monica Morrow; Gary A Ulaner
Journal:  J Nucl Med       Date:  2015-08-20       Impact factor: 10.057

3.  Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer.

Authors:  David Groheux; Sylvie Giacchetti; Jean-Luc Moretti; Raphael Porcher; Marc Espié; Jacqueline Lehmann-Che; Anne de Roquancourt; Anne-Sophie Hamy; Caroline Cuvier; Laetitia Vercellino; Elif Hindié
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-11-06       Impact factor: 9.236

4.  Rate of Distant Metastases on 18F-FDG PET/CT at Initial Staging of Breast Cancer: Comparison of Women Younger and Older Than 40 Years.

Authors:  Vincent Lebon; Jean-Louis Alberini; Jean-Yves Pierga; Véronique Diéras; Nina Jehanno; Myriam Wartski
Journal:  J Nucl Med       Date:  2016-09-01       Impact factor: 10.057

5.  Prospective study of 2-[¹⁸F]fluorodeoxyglucose positron emission tomography in the assessment of regional nodal spread of disease in patients with breast cancer: an Ontario clinical oncology group study.

Authors:  Kathleen I Pritchard; Jim A Julian; Claire M B Holloway; David McCready; Karen Yvonne Gulenchyn; Ralph George; Nicole Hodgson; Peter Lovrics; Francisco Perera; Leela Elavathil; Frances P O'Malley; Nancy Down; Audley Bodurtha; Wendy Shelley; Mark N Levine
Journal:  J Clin Oncol       Date:  2012-03-05       Impact factor: 44.544

6.  18F-FDG-PET/CT for systemic staging of patients with newly diagnosed ER-positive and HER2-positive breast cancer.

Authors:  Gary A Ulaner; Raychel Castillo; Jonathan Wills; Mithat Gönen; Debra A Goldman
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-04-29       Impact factor: 9.236

7.  A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases.

Authors:  U Veronesi; C De Cicco; V E Galimberti; J R Fernandez; N Rotmensz; G Viale; G Spano; A Luini; M Intra; P Veronesi; A Berrettini; G Paganelli
Journal:  Ann Oncol       Date:  2006-12-12       Impact factor: 32.976

8.  (18)F-FDG-PET/CT for systemic staging of newly diagnosed triple-negative breast cancer.

Authors:  Gary A Ulaner; Raychel Castillo; Debra A Goldman; Jonathan Wills; Christopher C Riedl; Katja Pinker-Domenig; Maxine S Jochelson; Mithat Gönen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-04-30       Impact factor: 9.236

9.  Retrospective analysis of 18F-FDG PET/CT for staging asymptomatic breast cancer patients younger than 40 years.

Authors:  Christopher C Riedl; Elina Slobod; Maxine Jochelson; Monica Morrow; Debra A Goldman; Mithat Gonen; Wolfgang A Weber; Gary A Ulaner
Journal:  J Nucl Med       Date:  2014-09-11       Impact factor: 10.057

Review 10.  ¹⁸F-FDG PET/CT for Staging and Restaging of Breast Cancer.

Authors:  David Groheux; Alexandre Cochet; Olivier Humbert; Jean-Louis Alberini; Elif Hindié; David Mankoff
Journal:  J Nucl Med       Date:  2016-02       Impact factor: 10.057
View more
  3 in total

1.  Diagnostic Performance of F18-FDG PET/CT in Male Breast Cancers Patients.

Authors:  Andra Piciu; Doina Piciu; Narcis Polocoser; Anita A Kovendi; Iulia Almasan; Alexandru Mester; Dragos-Stefan Morariu; Calin Cainap; Simona Sorana Cainap
Journal:  Diagnostics (Basel)       Date:  2021-01-13

2.  Hormonal Receptor Immunochemistry Heterogeneity and 18F-FDG Metabolic Heterogeneity: Preliminary Results of Their Relationship and Prognostic Value in Luminal Non-Metastatic Breast Cancers.

Authors:  Nicolas Aide; Nicolas Elie; Cécile Blanc-Fournier; Christelle Levy; Thibault Salomon; Charline Lasnon
Journal:  Front Oncol       Date:  2021-01-12       Impact factor: 6.244

3.  Role of 18F-Fluorodeoxyglucose Positron-Emission Tomography/Computed Tomography Scan in Primary Staging of Breast Cancer Compared to Conventional Staging.

Authors:  Naveen Kumar Reddy Akepati; Zakir Ali Abubakar; Prathyusha Bikkina
Journal:  Indian J Nucl Med       Date:  2018 Jul-Sep
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.